Potential of BCL2 as a target for chronic lymphocytic leukemia treatment

Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Chiara Favini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ahad Ahmed Kodipad(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Fary Diop(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Expert Review of Hematology
March 21, 2018
10.1080/17474086.2018.1456332
Cited by 19

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|216
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
|Journal of Clinical Oncology|2014|210